Found: 26
Select item for more details and to access through your institution.
Associations of weight loss with obesity‐related comorbidities in a large integrated health system.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2804, doi. 10.1111/dom.14538
- By:
- Publication type:
- Article
Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2795, doi. 10.1111/dom.14537
- By:
- Publication type:
- Article
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2785, doi. 10.1111/dom.14536
- By:
- Publication type:
- Article
Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first‐line oral therapy for type 2 diabetes: A claims‐based observational cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2741, doi. 10.1111/dom.14530
- By:
- Publication type:
- Article
Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2763, doi. 10.1111/dom.14534
- By:
- Publication type:
- Article
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2819, doi. 10.1111/dom.14533
- By:
- Publication type:
- Article
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2752, doi. 10.1111/dom.14532
- By:
- Publication type:
- Article
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2775, doi. 10.1111/dom.14535
- By:
- Publication type:
- Article
Biologically plausible trends suggesting that a low‐protein diet may enhance the effect of flozination caused by the sodium‐glucose cotransporter‐2 inhibitor dapagliflozin on albuminuria.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2825, doi. 10.1111/dom.14524
- By:
- Publication type:
- Article
A global country‐level analysis of the relationship between obesity and COVID‐19 cases and mortality.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2697, doi. 10.1111/dom.14523
- By:
- Publication type:
- Article
Glucose control using fast‐acting insulin aspart in a real‐world setting: A 1‐year, two‐centre study in people with type 1 diabetes using continuous glucose monitoring.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2716, doi. 10.1111/dom.14527
- By:
- Publication type:
- Article
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2707, doi. 10.1111/dom.14525
- By:
- Publication type:
- Article
Completion of annual diabetes care processes and mortality: A cohort study using the National Diabetes Audit for England and Wales.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2728, doi. 10.1111/dom.14528
- By:
- Publication type:
- Article
Do lifestyle interventions reduce diabetes incidence in people with isolated impaired fasting glucose?
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2660, doi. 10.1111/dom.14518
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2679, doi. 10.1111/dom.14520
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2670, doi. 10.1111/dom.14519
- By:
- Publication type:
- Article
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2687, doi. 10.1111/dom.14522
- By:
- Publication type:
- Article
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2814, doi. 10.1111/dom.14517
- By:
- Publication type:
- Article
Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2651, doi. 10.1111/dom.14516
- By:
- Publication type:
- Article
Effectiveness of a ketogenic diet and virtual coaching intervention for patients with diabetes: A difference‐in‐differences analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2643, doi. 10.1111/dom.14515
- By:
- Publication type:
- Article
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2632, doi. 10.1111/dom.14513
- By:
- Publication type:
- Article
Validation of obesity‐related diagnosis codes in claims data.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2623, doi. 10.1111/dom.14512
- By:
- Publication type:
- Article
Effects of 1‐year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2614, doi. 10.1111/dom.14508
- By:
- Publication type:
- Article
Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the Australian National Diabetes Audit from 2013 to 2019.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2603, doi. 10.1111/dom.14506
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2601, doi. 10.1111/dom.13786
- Publication type:
- Article